Which company received FDA approval in 2022 for a gene therapy targeting a rare

Practice Questions

Q1
Which company received FDA approval in 2022 for a gene therapy targeting a rare genetic disorder?
  1. Novartis
  2. Bluebird Bio
  3. Spark Therapeutics
  4. CRISPR Therapeutics

Questions & Step-by-Step Solutions

Which company received FDA approval in 2022 for a gene therapy targeting a rare genetic disorder?
  • Step 1: Identify the year in question, which is 2022.
  • Step 2: Look for companies that received FDA approval in that year.
  • Step 3: Focus on gene therapies that were approved.
  • Step 4: Find out which gene therapy targets a rare genetic disorder.
  • Step 5: Confirm that Bluebird Bio received FDA approval for its gene therapy.
  • Step 6: Specify that the gene therapy targets beta-thalassemia, a rare genetic blood disorder.
No concepts available.
Soulshift Feedback ×

On a scale of 0–10, how likely are you to recommend The Soulshift Academy?

Not likely Very likely